Clinical Trials
38 trialsNCT06608940 2026-02-19
BC3402 w/ Tremelimumab + Durvalumab (STRIDE) in Hepatocellular Carcinoma
Case Comprehensive Cancer Center
Phase 1/2 Withdrawn
NCT03879161 2025-10-16
A Percutaneous Ultrasound Device With Needle Guide for Vascular Access
Johns Hopkins University
Phase NA Withdrawn
NCT06690281 2025-09-11
A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies
National Institutes of Health Clinical Center (CC)
Phase 2 Withdrawn
NCT02939807 2025-04-27
A Phase II Study of ABC294640 as Monotherapy in Patients With Advanced Hepatocellular Carcinoma
Medical University of South Carolina
Phase 2 Withdrawn
NCT06144827 2025-03-18
HepQuant
Montefiore Medical Center
Phase NA Withdrawn
NCT02853500 2025-02-05
Effect of Surefire Infusion Device on Tumor Response to Regional Intra-arterial Therapy for Primary Liver Malignancies
Dana-Farber Cancer Institute
Phase 4 Withdrawn
NCT04931420 2024-07-31
Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels
University of Chicago
Phase 2 Withdrawn
NCT05471401 2024-06-13
GI Organ Tracking Via Balloon Applicators
Washington University School of Medicine
Phase NA Withdrawn
NCT05641922 2023-11-27
PANORAMA2
Techsomed Medical Technologies LTD
Phase NA Withdrawn
NCT05510427 2023-08-15
Phase Ib Trial of Infigratinib In Combination With Atezolizumab And Bevacizumab for The Second-Line Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion/Amplification
M.D. Anderson Cancer Center
Phase 1 Withdrawn
NCT05109052 2023-07-13
Trial of PXS-5505 Combined With First Line Atezolizumab Plus Bevacizumab For Treating Patients With Unresectable Hepatocellular Carcinoma
University of Rochester
Phase 1/2 Withdrawn
NCT05039736 2023-05-12
A Phase II Study to Evaluate the Effects of Sequential Therapy With the Anti c-MET/VEGFR Tyrosine Kinase Inhibitor (TKI), Cabozantinib, Followed by an Anti-PD-1 Antibody (Nivolumab) in Patients With Advanced HCC Who Progressed on First-line Therapy
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT00430313 2023-03-29
Effects of Acupoint Electro-stimulation on Preventing Nausea and Vomiting Induced by Cisplatin or Oxaliplatin
M.D. Anderson Cancer Center
Phase NA Withdrawn
NCT04105062 2021-12-09
LS301 Uptake in Tumors of Patients Undergoing Liver, Pancreas, or Gastric Surgery
Washington University School of Medicine
Phase 1/2 Withdrawn
NCT04511793 2021-07-19
Hepatic Artery Infusion (HAI) Program at Duke University
Duke University
Phase NA Withdrawn
NCT03452553 2021-04-21
Study in the Treatment of HCC With a Radiopaque (RO) Bead (LC Bead LUMIā¢) Loaded With Doxorubicin
Boston Scientific Corporation
Phase NA Withdrawn
NCT03215355 2021-01-27
Improving CBCT for Liver IG-SBRT Using Gadoxetate Disodium
Nova Scotia Health Authority
Phase 4 Withdrawn
NCT03063840 2020-11-20
Microwave Ablation for the Treatment of Malignant Liver Tumors Closed to Intrahepatic Vessels
National Taiwan University Hospital
Phase NA Withdrawn
NCT03484962 2020-10-19
Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Liver Cancer
Fuda Cancer Hospital, Guangzhou
Phase 2 Withdrawn
NCT00020774 2020-07-31
SCH 66336 With or Without Gemcitabine Followed by Surgery Compared With Surgery Alone in Treating Patients With Primary Liver Cancer
Jonsson Comprehensive Cancer Center
Phase 2 Withdrawn
NCT02989870 2020-06-05
Sorafenib and Bavituximab Plus SBRT in Unresectable Hepatocellular Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Withdrawn
NCT01923233 2020-01-22
In-Situ Therapeutic Cancer Vaccine for Refractory Liver Cancer
Mirror Biologics, Inc.
Phase 1/2 Withdrawn
NCT01995227 2020-01-22
An Individualized Anti-Cancer Vaccine Study in Patients With HCC
Mirror Biologics, Inc.
Phase 1/2 Withdrawn
NCT02288507 2019-11-08
Sorafenib Concurrent With Yttrium-90 Transarterial Radioembolization in Patients With Advanced Hepatocellular Cancer
University of Hawaii
Phase 1 Withdrawn
NCT03345225 2018-09-11
A Clinical Study of Precision TACE (P-TACE) With Surefire
University of Miami
Phase NA Withdrawn
NCT00039078 2017-06-26
Radiolabeled Glass Beads (TheraSphereĀ®) in Treating Patients With Primary Liver Cancer That Cannot Be Removed by Surgery
University of Pittsburgh
Phase 2 Withdrawn
NCT01882218 2017-05-05
Direct Peritoneal Resuscitation Plus Conventional Resuscitation
University of Louisville
Phase 4 Withdrawn
NCT02261844 2017-03-30
Resveratrol and Human Hepatocyte Function in Cancer
University of Louisville
Phase 1/2 Withdrawn
NCT00510627 2017-03-03
Prometheus
Boston Scientific Corporation
Phase 4 Withdrawn
NCT01711450 2016-03-23
Success of Paravertebral Blocks in Analgesia for Interventional Hepatic Procedures
McGill University Health Centre/Research Institute of the McGill University Health Centre
Phase NA Withdrawn
NCT00244348 2015-08-27
Hepatic Artery Infusion With Oxaliplatin
Medical College of Wisconsin
Phase 1/2 Withdrawn
NCT00624962 2014-12-11
Early Enteral Tube Feedings in Children Receiving Chemo for AML/MDS & High Risk Solid Tumors
Vanderbilt University
Phase NA Withdrawn
NCT01864070 2014-07-22
Phase 1 TheraSphere + Everolimus With Neuroendocrine Tumors (NETs) + Liver Only or Liver Dominant Disease
M.D. Anderson Cancer Center
Phase 1 Withdrawn
NCT01618253 2013-09-05
Radiation Therapy With Sorafenib for TACE-Resistant Hepatocellular Carcinoma
Medical College of Wisconsin
Phase 1 Withdrawn
NCT01281943 2013-07-04
Study of Pegylated Liposomal Doxorubicin and Temsirolimus in Patients With Advanced Hepatocellular Cancer
Washington University School of Medicine
Phase 2 Withdrawn
NCT00093548 2012-10-04
Vaccine Therapy in Treating Patients With Stage II, Stage IIIA, Stage IIIB, or Stage IVA Liver Cancer
Jonsson Comprehensive Cancer Center
Phase 1/2 Withdrawn
NCT00293436 2012-09-17
Celecoxib and Erlotinib in Treating Patients With Liver Cancer
University of California, San Francisco
Phase 1/2 Withdrawn
NCT00003714 2012-02-22
Chemotherapy in Treating Patients With Unresectable Primary or Metastatic Kidney Cancer
M.D. Anderson Cancer Center
Phase 2 Withdrawn